Targeting the Root: How Gene Editing Could End Lifelong Hepatitis B Treatment

DURHAM, N.C. – November 05, 2026 – For the more than 250 million people globally living with chronic hepatitis B, the current standard of care is a grueling, lifelong commitment. Existing daily antiviral medications are highly effective at suppressing the virus, but they harbor a critical flaw: they cannot eliminate the root cause of the infection. As a result, patients remain tethered to the pharmacy counter, constantly managing a condition that carries the looming threats of cirrhosis and liver cancer.

But the landscape of infectious disease management is shifting. Precision BioSciences, a clinical-stage biotechnology company based in North Carolina, has unveiled compelling new data that strips away the speculative hype often surrounding gene editing, replacing it with tangible, clinical evidence. Presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2026, the updated Phase 1 findings for the company's PBGENE-HBV therapy suggest that a finite, curative treatment for chronic hepatitis B may finally be within reach.

Attacking the Viral Reservoir

The central obstacle to curing hepatitis B lies deep within the liver cells in the form of covalently closed circular DNA (cccDNA). This persistent genetic reservoir acts as a viral factory, continuously churning out new infectious particles. Traditional nucleos(t)ide analogs only block the virus downstream; they do not touch the cccDNA.

Precision BioSciences is utilizing its proprietary ARCUS genome editing platform to directly target and eliminate this cccDNA. The latest data from the ongoing ELIMINATE-B trial provides robust biomarker and biopsy evidence that the therapy is working as intended. According to the company, 100 percent of evaluable patients treated at the optimal dose of 0.4 mg/kg achieved complete and durable loss of pregenomic RNA (pgRNA)—a key blood-based biomarker that indicates cccDNA activity. Impressively, this undetectable status has been sustained for nearly a year in patients with long-term follow-up.

Even more critical is the physical evidence extracted from the liver. Paired liver biopsies from two patients treated at the 0.4 mg/kg dose demonstrated 10-fold and 35-fold reductions in cccDNA.

"For patients with chronic hepatitis B, the persistent viral reservoir remains the central obstacle to achieving a cure," said Dr. Man-Fung Yuen, lead investigator of the ELIMINATE-B study and Chair Professor at The University of Hong Kong. "Reproducing the liver biopsy evidence of cccDNA elimination in a second patient treated at 0.4 mg/kg, together with durable pgRNA loss in patients with longer follow-up, is particularly important because it links the intended mechanism of action, cccDNA elimination, to ongoing antiviral activity."

The trial also achieved a significant milestone by demonstrating profound efficacy in a harder-to-treat demographic. The first HBeAg-positive patient treated in the study—a population characterized by logarithmically higher viral loads—achieved undetectable pgRNA after just two administrations of the therapy, dropping from a baseline of 5,750 copies/mL.

Navigating the Safety Profile of Repeat Dosing

In the realm of in vivo gene editing, proving efficacy is only half the battle; the delivery mechanism often presents the greatest hurdle. PBGENE-HBV relies on lipid nanoparticles (LNPs) to transport the ARCUS nuclease mRNA into liver cells. While LNPs are effective, repeat dosing historically triggers inflammatory immune responses.

However, Precision BioSciences has managed to navigate this bottleneck. Across 59 administrations in 25 patients, the therapy maintained a highly manageable safety profile with no dose-limiting toxicities. The most common adverse events were standard infusion-related reactions that resolved within 24 hours.

While transient elevations in liver enzymes (ALT and AST) were observed—a known effect of LNP clearance—they were asymptomatic and resolved without intervention. Crucially, at the selected Phase 2 dose of 0.4 mg/kg, no serious adverse events occurred. The decision to cap the dose at 0.4 mg/kg, rather than pushing to the 0.65 mg/kg cohort, reflects a pragmatic approach to balancing potent antiviral activity with patient tolerability.

The Competitive Landscape: Suppression vs. Elimination

The race to cure chronic hepatitis B is crowded, but PBGENE-HBV occupies a unique lane. Rival pharmaceutical giants are aggressively pursuing functional cures using RNA interference (RNAi) and antisense oligonucleotides (ASOs). Companies like Arrowhead Pharmaceuticals, Alnylam, and GSK have programs designed to silence viral mRNA, leading to significant drops in the hepatitis B surface antigen (HBsAg).

Yet, these approaches fundamentally differ from ARCUS. "While knocking down viral proteins with RNA interference offers a functional reprieve, it leaves the viral factory intact," observed one independent biotechnology analyst reviewing the AASLD data. "Precision's data suggests we might actually be able to dismantle the factory itself. If you destroy the cccDNA, the suppression of surface antigens naturally follows, but with the added permanence of a true viral cure."

The data supports this thesis. Precision reported that all 24 evaluable patients across dose levels experienced reductions in HBsAg, with maximal reductions approaching 94 percent at the 0.4 mg/kg dose. By aligning its clinical endpoints with the FDA's validated marker for a viral cure—sustained undetectable HBV DNA off therapy—Precision is positioning PBGENE-HBV not just as a treatment, but as a definitive resolution.

De-Risking the Path to Phase 2

Scientific breakthroughs require corporate endurance. Taking a gene editing therapy from early-stage promise to global commercialization demands immense capital and operational discipline. Precision BioSciences appears to be fortifying its foundation for the long haul.

Financially, the company is moving into the next phase of development from a position of relative strength. Reporting its third-quarter results earlier this month, Precision noted a cash position of approximately $108 million. Combined with a recently priced $125 million underwritten offering of common stock and pre-funded warrants, the company projects a financial runway extending through 2028. This capital injection is critical, ensuring the company has the resources to execute its ambitious clinical roadmap without the immediate distraction of fundraising.

With the 0.4 mg/kg dose officially locked in, Precision is finalizing protocols for the ELIMINATE-B2 Phase 2 study, slated to begin dosing in the first quarter of 2027. The upcoming trial will evaluate PBGENE-HBV not only as a monotherapy but also in combination with an ASO, testing whether a multi-pronged attack can accelerate functional and viral cure rates across a diverse global patient population.

"Patients have long desired a cure for their virus and living a life free from daily medication - today’s data is a step in that direction," said Michael Amoroso, President and Chief Executive Officer of Precision BioSciences.

As the biotechnology sector continues to mature, the focus is rightfully shifting from the theoretical elegance of gene editing to its practical execution in human beings. Precision BioSciences’ latest data readout offers a sobering but highly optimistic look at what the future of medicine can achieve when we stop merely managing diseases and start engineering their eradication.